Who is sponsoring NCT04550910?

NCT04550910 is sponsored by National Cancer Institute, Egypt.

What drugs are being tested in NCT04550910?

Interventions in NCT04550910: Hypofractionation Schedules for Breast Cancer patients after mastecomy.

What condition does NCT04550910 study?

NCT04550910 studies Radiotherapy Side Effect, Locoregional Recurrence.

Is NCT04550910 still recruiting?

NCT04550910 is currently status unknown. Last updated 16 September 2020.

Last reviewed 2020-09-16 · How we verify

NCT04550910: Breastcancer

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RCT Comparing 2 Radiotherapy HypoFractionation Schedules In Breast Cancer Patients

Status unknown NA Last updated 16 September 2020

What this trial tests

NA trial testing Hypofractionation Schedules for Breast Cancer patients after mastecomy in Radiotherapy Side Effect in 166 participants. Status unknown.

Timeline

1 January 2020

Primary endpoint
1 June 2021

1 February 2022

Quick facts

Lead sponsor	National Cancer Institute, Egypt
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	other
Enrollment	166
Start date	1 January 2020
Primary completion	1 June 2021
Estimated completion	1 February 2022
Sites	1 location across Egypt

Drugs / interventions tested

Hypofractionation Schedules for Breast Cancer patients after mastecomy

Conditions studied

Radiotherapy Side Effect — all drugs for Radiotherapy Side Effect →
Locoregional Recurrence — all drugs for Locoregional Recurrence →

Sponsor

National Cancer Institute, Egypt

Who can join

Adults 18 to 75, female only, with Radiotherapy Side Effect or Locoregional Recurrence. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a prospective randomized Phase III trial to assess efficiency of two post mastectomy hypofractionation schedules (40 Gy /15 fx / 3 weeks, 5 days per week VS 28.5 Gy delivered in 5 once-weekly fractions of 5.7 Gy each week) as adjuvant radiotherapy in female patients with breast cancer after mastectomy.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Ultra-hypofractionated one-week locoregional radiotherapy for patients with early breast cancer: Acute toxicity results.
Ratosa I, Montero A, Ciervide R, Alvarez B, et al · · 2024 · cited 6× · PMID 38516338 · DOI 10.1016/j.ctro.2024.100764
Chimeric Antigen Receptor T-cell therapy in systemic autoimmune rheumatic diseases: current insights and future prospects.
Lee BW, Kwon EJ, Ju JH. · · 2025 · PMID 40584766 · DOI 10.4078/jrd.2024.0122

Verify or expand the search:

Other recruiting trials for Radiotherapy Side Effect

Currently open trials in the same condition.

NCT06950073 — Curatively Intended Thoracic Reirradiation · recruiting
NCT06311955 — Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor · Phase 2 · recruiting
NCT07008716 — Omitting CTV for Primary Tumor in LS-SCLC · Phase 3 · recruiting
NCT06758830 — Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. · Phase 2, PHASE3 · recruiting
NCT06752239 — Prophylactic Radiotherapy Optimization for Enhanced Thyroid Function Protection in NPC · Phase 3 · recruiting

Other National Cancer Institute, Egypt trials

Trials by the same sponsor.

NCT07424638 — Interscalene Block Versus Anterior Suprascapular Block for Post-Thoracotomy Shoulder Pain · NA · recruiting
NCT07367568 — Costotransverse Foramen Block With Erector Spinae Plane Block in Modified Radical Mastectomy · NA · recruiting
NCT07367581 — Costotransverse Foramen Block Versus Thoracic Paravertebral Block in Thoracotomy for Lung Cancer · NA · recruiting
NCT07337330 — Ultrasound Guided External Oblique Intercostal Plane Block Versus Erector Spinae Block for Post Hepatectomy Pain · NA · not yet recruiting
NCT07390448 — Rhomboid Intercostal Sub-serratus Plane Blocks and Erector Spinae Plane Block in Mastectomy Surgeries · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04550910 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Cancer Institute, Egypt
Last refreshed: 16 September 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04550910.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing